New 'Living Drug' tested in fight against tough cancers
NCT ID NCT06464965
Summary
This early-stage study tested a new type of cell therapy for people with advanced stomach or pancreatic cancer that has stopped responding to standard treatments. Doctors gave 10 patients immune cells from donated cord blood that were engineered to attack a specific protein found on these cancer cells. The main goal was to find the highest safe dose and check for side effects, while also seeing if the treatment could help shrink or control the tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.